Jack O’Meara, co-founder and CEO of Ochre Bio, sits down with Neil to discuss the large unmet health need created by chronic liver disease and the company’s efforts to develop RNA therapies address it.

Tim Lu, co-founder and CEO of Senti Bio, sits down with Neil to discuss how his company is using synthetic biology to engineer cell and gene therapies with programmable gene circuits to make therapies that are safer, more effective, and precise.

On this episode, Neil sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs.

Matt De Silva, founder and executive chairman of Notable Labs, sits down with Neil to discuss his company’s predictive precision medicine platform and its move to leverage its platform to develop its own precision cancer therapies.

Dennis Purcell, founder of Aisling Capital and former managing director of the Life Sciences Investment Banking Group at Chase H&Q, sits down with Neil discuss where biotech has been and what's ahead for the sector.

On this episode, Arnaud Lacoste, Chief Scientific Officer of Aurion Biotech, sits down with Neil Littman to discuss the company’s experimental cell therapy to restore vision in patients with corneal endothelial disease.

Kareem Barghouti, co-founder and CEO of VastBiome, sits down with Neil to discuss how his company is using AI to map the gut microbiome to discover novel therapies.

Congratulations to the Volumetric team on their acquisition by 3D Systems!

Viswa Colluru, founder and CEO of Enveda Bio sits down with Neil to discuss AI in drug development, and the challenges of managing and forging a TechBio culture.